Vilin Bio Med is a pharmaceutical manufacturer that has spent two decades as a quiet supplier of unbranded generic medicines to other drug companies - and is now being reshaped by new owners into something far broader. Originally set up in Hyderabad in 2005 and listed on the NSE’s small-company platform in mid-2023, the company has always made its products using in-house know-how and sold them in bulk, never under its own label. The recurring pattern is a business that operates behind the scenes - it manufactures for others, it is now entering trading and devices through partnerships, and it is absorbing a chemical-research firm through a merger, each time letting someone else’s brand or demand pull the product through.
Business segments
A single manufacturing engine that makes generic liquid, tablet and capsule formulations for other pharma companies to brand and sell - now being extended into API research, medical devices and US trading through a series of deals that have not yet begun commercial production.
1. Contract formulation manufacturing: the unbranded supplier behind other companies’ labels
The company makes oral liquids, tablets, capsules and external preparations at its Roorkee plant and sells the entire output in bulk to other pharmaceutical manufacturers and traders - it owns no consumer brand and earns no retail margin.
- Makes three dosage forms under one roof - the plant produces oral liquids (syrups, suspensions and dry powders), tablets and capsules, and external preparations, covering the most common formats that downstream buyers need.
- Sold in bulk, never branded - every product leaves the factory without a brand name, going directly to pharmaceutical manufacturers, marketers and traders who then package, label and distribute it through their own channels.
- In-house know-how, no outside technology - the company does not license any external manufacturing technology; all processes are developed and run internally, which keeps the operation simple and avoids royalty costs.
- A single plant in Uttarakhand - the manufacturing unit sits at Madhopur Village in Roorkee, Haridwar district, and as of late 2024 the company was upgrading the facility to meet DCGI (Drugs Controller General of India) guidelines, with production expected to resume shortly after the upgrade.
- Domestic-only, with a concentrated customer base - as of the half-year to September 2024, all sales were within India, and in earlier years a meaningful portion of revenue came from a handful of related-party buyers such as Redizen Lifesciences and Spectrogen International, all at arm’s-length terms.
Group structure and partners
A standalone company with no subsidiaries or joint ventures, now under a completely new promoter group that acquired control in 2025 and immediately set about reshaping the business through a merger and two new ventures.
- No subsidiaries, associates or joint ventures - Vilin Bio Med has always operated as a single legal entity with no foreign investments or collaborations, which means all its activities sit on one balance sheet.
- A merger will bring API research in-house - in February 2026, the board approved a scheme to absorb Chemgenix Laboratories Private Limited, a company that researches, develops and manufactures Active Pharmaceutical Ingredients (APIs) and specialty chemicals, through a share-for-share merger that will raise the combined entity’s promoter holding to about 74%.
- Two new bets - US trading and Kerala medical devices - in January 2026, the company announced it had entered the export and import of pharmaceutical products in the United States, and signed an expression of interest with the Kerala government to explore investing roughly ₹100 crore in a medical-device manufacturing facility. Neither venture had begun commercial operations at the time of the announcement.